Meiji (2269) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
1 Nov, 2026Executive summary
FY2023 net sales and operating profit grew, while profit attributable to owners of parent declined; the FY2024–2026 plan targets renewed growth through overseas expansion, portfolio changes and stronger capital efficiency.
Priorities include investing in growth businesses, sustaining stable cash flows, linking sustainability to business strategy and developing human capital.
Financial highlights
FY2023 net sales were ¥1,105.4bn, up 4.1% YoY; operating profit was ¥84.3bn, up 11.8%.
Ordinary profit rose 2.5% to ¥76.0bn; profit attributable to owners of parent fell 27.0% to ¥50.6bn.
Operating cash flow was ¥107.9bn and free cash flow was ¥83.3bn, respectively up ¥22.9bn and ¥35.1bn YoY.
Outlook and guidance
FY2024 plan: net sales ¥1,159.0bn (+4.8% YoY), operating profit ¥86.0bn (+2.0%) and profit attributable to owners of parent ¥50.0bn (-1.3%).
FY2026 targets: operating profit ¥116.5bn, profit attributable to owners of parent ¥76.5bn, overseas net sales ¥252.5bn and ROIC of at least 8.5%.
FY2026 shareholder return target: total payout ratio of at least 50%; ROE target is at least 9.5%.
Latest events from Meiji
- Q1 operating profit up 27.7% YoY, with strong Food and Pharma growth and China business transfer.2269
Q1 2027 - FY 2025 profit beat plan on pharma strength; FY 2026/2027 targets growth and ROE recovery.2269
Q4 2026 - Impairment in China drives restructuring, with renewed focus on growth, ROE, and innovation.2269
Investor presentation - Operating profit rose on Food segment strength, but net profit fell on higher costs and impairment.2269
Q3 2026 - Operating profit beat plan, but sales forecast lowered amid cost pressures and reforms.2269
Q2 2026 - Profits declined in Q1, but full-year outlook and dividend plans remain strong.2269
Q1 2026 - Pharmaceuticals drove profit growth as food margins fell; full-year outlook and share cancellation steady.2269
Q2 2025 - Sales and profit rose, led by pharmaceuticals, despite food margin pressures.2269
Q1 2025 - Sales and profit growth continue, with higher dividends and strategic investments ahead.2269
Q4 2025